INTRODUCTION:

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the degeneration of dopaminergic neurons in the substantia nigra, lea1ding to cardinal motor symptoms such as tremors, bradykinesia, rigidity, and postural instability. Globally, PD affects approximately 1% of individuals over the age of 60, and its prevalence is expected to rise significantly due to increasing life expectancy and aging populations^1,2.

Conventional pharmacological treatments, primarily based on dopamine replacement therapy like levodopa, offer symptomatic relief but fail to halt disease progression. Over time, patients often experience motor fluctuations and dyskinesias, which diminish the long-term efficacy of medication. Surgical interventions, such as lesioning procedures, have shown some benefits but are invasive and irreversible.

In recent decades, a novel class of therapeutic technology known as bioelectroceuticals has emerged, offering a revolutionary approach to managing neurological disorders. Bioelectroceuticals utilize precisely targeted electrical impulses to modulate abnormal neural circuit activity, providing symptomatic relief without the systemic side effects associated with medications. Among these, central nervous system (CNS) implants, particularly deep brain stimulation (DBS) devices, have garnered significant attention in the treatment of Parkinson’s disease³.

This review aims to provide a comprehensive overview of bioelectroceuticals, with a special focus on CNS implants in Parkinson’s disease. It highlights their mechanism of action, clinical effectiveness, recent technological advancements, challenges, and future prospects in neurotherapeutics.

WHAT ARE BIOELECTROCEUTICALS?

Bioelectroceuticals, also referred to as electroceuticals or neuromodulation therapies, represent a rapidly evolving class of medical treatments that use electrical stimulation to modify or regulate nervous system activity. Unlike traditional pharmacological therapies that rely on chemical agents to modulate biological functions, bioelectroceuticals utilize precisely controlled electrical impulses to influence targeted neural circuits, offering a more localized and often reversible method of treatment⁴.

The concept of using electricity for medical purposes dates back to the 18th century; however, the modern field of bioelectroceuticals has gained momentum in the last two decades with the advancement of implantable electronic devices. These devices are designed to interface directly with the nervous system, either by stimulating specific brain regions, spinal cord pathways, or peripheral nerves, depending on the therapeutic goal.

In the context of neurodegenerative diseases like Parkinson’s disease, bioelectroceutical devices—particularly central nervous system (CNS) implants—are used to restore functional balance within dysregulated neural circuits. By delivering electrical signals to predetermined brain areas, these devices can significantly alleviate motor symptoms, improve quality of life, and reduce the dependence on pharmacological treatments.

Bioelectroceuticals are increasingly being explored not only for movement disorders like PD but also for other conditions such as epilepsy, depression, chronic pain, and even inflammatory diseases. Their unique ability to target the nervous system directly makes them a promising alternative or adjunct to conventional therapies in modern medicine⁵.

CENTRAL NERVOUS SYSTEM (CNS) IMPLANTS IN PARKINSON’S DISEASE

Central nervous system (CNS) implants, particularly deep brain stimulation (DBS) systems, have transformed the management of advanced Parkinson’s disease by providing symptomatic relief through targeted electrical stimulation of specific brain regions. DBS is the most established and widely used form of CNS implant in Parkinson’s therapy, approved by regulatory authorities such as the FDA and widely adopted in clinical practice worldwide.

The fundamental principle of CNS implants in PD involves the implantation of electrodes into particular brain nuclei—most commonly the subthalamic nucleus (STN) or the globus pallidus interna (GPi). These electrodes are connected to a pulse generator, typically implanted subcutaneously in the chest, which delivers continuous or adaptive electrical impulses. The stimulation modulates abnormal neuronal firing patterns associated with PD, leading to improvement in motor symptoms like tremors, rigidity, and bradykinesia^6,7.

Recent technological advancements have led to the development of closed-loop DBS systems, which adjust stimulation parameters in real time based on the patient's neural activity, potentially reducing side effects and improving therapeutic outcomes. Furthermore, directional leads, rechargeable pulse generators, and MRI-compatible devices have enhanced the safety, precision, and convenience of CNS implants⁸.

Beyond DBS, emerging bioelectroceutical strategies such as optogenetic stimulation, vagus nerve stimulation (VNS), and adaptive biofeedback systems are being investigated for Parkinson’s disease. These newer technologies aim to offer more personalized neuromodulation with fewer complications.

CNS implants have not only expanded therapeutic options for patients with advanced PD who are refractory to medications but have also opened new avenues of research in neuromodulation therapies for a range of neurological disorders⁹.

Figure no. 1: Deep Brain Stimulation

CLINICAL APPLICATIONS AND BENEFITS

The clinical application of bioelectrical CNS implants, primarily through deep brain stimulation (DBS), has revolutionized the treatment landscape for patients with advanced Parkinson’s disease. Numerous clinical studies and long-term follow-up reports have demonstrated that DBS provides significant and sustained improvement in the motor symptoms of PD^8,9.

One of the most important clinical benefits of CNS implants is the reduction in motor fluctuations and dyskinesias that typically develop after long-term use of dopaminergic medications. DBS enables patients to achieve more consistent motor control with reduced "off" periods and fewer involuntary movements, thus minimizing the reliance on high doses of medication⁹.

In addition to motor symptom control, DBS has been shown to improve several non-motor symptoms, including mood disturbances, sleep quality, and overall quality of life. Some patients also experience improvement in tremor-resistant symptoms, such as gait freezing, although this benefit is variable.

Further clinical advantages include:

· Reversibility and adjustability: Unlike ablative surgeries, DBS can be adjusted or turned off, allowing for personalized management based on patient response.

· Long-term efficacy: Studies indicate that the benefits of DBS can last for several years, with appropriate adjustments and follow-up care.

· Reduced medication side effects: By lowering the need for dopaminergic drugs, CNS implants help reduce medication-induced complications such as hallucinations and nausea.

Expanding research into adaptive DBS (aDBS) and closed-loop systems suggests that future bioelectroceutical therapies could offer even greater improvements in clinical outcomes by providing real-time stimulation adjustments based on patient-specific neural biomarkers¹⁰.

Overall, CNS implants represent a major advancement in functional neurosurgery, offering Parkinson’s patients a safe, effective, and adjustable therapeutic option to regain independence and improve daily functioning.

Figure no. 2: Bioelectronic applications

CHALLENGES AND LIMITATIONS

While CNS implants and bioelectroceutical interventions have brought remarkable progress in the management of Parkinson’s disease, several challenges and limitations continue to affect their widespread adoption and clinical outcomes. These can be broadly categorized into surgical, device-related, clinical, and socioeconomic concerns.

Surgical Risks and Complications

CNS implants require invasive brain surgery, which carries inherent risks such as infection, bleeding, and hardware-related complications. Although major complications are rare in experienced centers, there remains a risk of:

- Intracranial hemorrhage

- Post-operative infection

- Lead migration or breakage

- Neurological deficits (in rare cases)

Device-Related Limitations

Despite technological advancements, CNS implants have certain mechanical and functional limitations:

- Battery life issues: Non-rechargeable pulse generators require replacement surgery every few years.

- Programming complexity: Optimizing stimulation settings requires multiple clinic visits and specialized expertise.

- Hardware malfunction: Though uncommon, device failures can lead to sudden symptom recurrence.

Variable Clinical Response

Not all patients experience uniform benefits from CNS implants. Clinical limitations include:

- Inconsistent improvement in non-motor symptoms

- Limited effect on axial symptoms like gait freezing and balance issues

- Progressive nature of Parkinson’s disease can lead to worsening of symptoms unrelated to dopaminergic pathways, which CNS implants cannot address.

Cost and Accessibility

High costs of surgery, devices, and follow-up care limit the availability of bioelectroceuticals, especially in low-resource settings. Key issues include:

- Expensive implantable devices

- Cost of post-surgical care and regular programming sessions

- Insurance coverage variability

Ethical and Psychological Considerations

The use of implanted devices raises ethical questions and psychological concerns in some patients:

- Patient anxiety related to surgery and device implantation

- Fear of device dependence

- Cultural or personal resistance to invasive brain procedures

Need for Specialized Care

Bioelectroceutical therapy requires a multidisciplinary team of neurologists, neurosurgeons, and specialized nursing staff. This concentration of expertise is often limited to major medical centers, restricting access for patients in rural or underserved regions¹¹.

RECENT RESEARCH, PATENTS, AND FUTURE PROSPECTS

The field of bioelectroceuticals for Parkinson’s disease is rapidly evolving, with ongoing innovations in technology, stimulation techniques, and device design. Recent research trends focus on improving therapeutic outcomes, reducing side effects, and developing more personalized neuromodulation strategies.

Recent Research Developments¹²

Recent clinical and preclinical studies have explored various advanced approaches to optimize CNS implants:

· Closed-Loop Deep Brain Stimulation (aDBS): Multiple studies have demonstrated that adaptive DBS, which adjusts stimulation in real-time based on local field potentials (LFPs), offers improved motor control with reduced stimulation time and fewer side effects.

· Directional Lead Technology: New-generation DBS systems with segmented leads allow directional steering of electrical current, improving efficacy and reducing stimulation-induced adverse effects.

· Optogenetics and Photostimulation: Experimental studies have introduced light-activated implants (optogenetics), offering highly selective neuronal activation in animal models of PD.

· Wireless and Miniaturized Implants: Ongoing research is focused on wireless neurostimulators and battery-free devices, enabling less invasive procedures and lower maintenance requirements.

· AI-based Stimulation Algorithms: Emerging research focuses on machine-learning-driven systems to predict symptom fluctuations and automatically modulate stimulation parameters.

Recent Patents¹³

Several patents have been filed globally, reflecting innovation in device design, adaptive stimulation, and patient-specific therapies:

· Patent US10888378B2 (2021): Adaptive closed-loop neuromodulation system for movement disorders, enabling real-time adjustments based on patient neural signals.

· Patent WO2022018469A1 (2022): A neurostimulation system with AI-controlled pulse modulation for optimized therapy in Parkinson’s disease.

· Patent IN202221035236 (India, 2022): Development of a non-invasive external stimulator targeting central pathways in early-stage Parkinson’s patients.

· Patent EP3698156B1 (2023): Implantable bioelectronic device with wireless recharging and remote programmability.

Ongoing patent trends show increasing interest in biofeedback-enabled, smart implantable devices, and wearable neurostimulation systems.

Emerging Inventions and Innovations

· Neurograins and Neural Dust: Tiny wireless micro-implants (neurograins) are being developed to form a neural network inside the brain, potentially offering high-resolution stimulation.

· Brain-Computer Interfaces (BCIs): Integrating BCIs with DBS for enhanced volitional control of stimulation.

· Peripheral Bioelectroceuticals: Exploration of vagus nerve and spinal cord stimulation as adjunct therapies for PD management.

· Energy Harvesting Implants: Research into devices that harvest energy from body movement or temperature to power implants without batteries.

Future Prospects

The future of bioelectroceuticals in Parkinson’s disease is promising, with several anticipated developments:

· Personalized Neuromodulation: Individualized stimulation programs based on patient-specific neural biomarkers.

· Minimally Invasive Implants: Development of smaller, less invasive devices to reduce surgical risks.

· Expanded Indications: Research into using CNS implants for early-stage PD and non-motor symptoms.

· Neurorestorative Approaches: Combining stimulation with neurotrophic factor delivery or stem cell therapies for disease-modifying effects.

Overall, these advancements highlight the transformative potential of bioelectroceuticals in delivering safer, more effective, and personalized care for patients with Parkinson’s disease.

CONCLUSION:

Bioelectroceuticals, particularly in the form of central nervous system (CNS) implants, have introduced a paradigm shift in the treatment of Parkinson’s disease by providing precise, adjustable, and often life-changing symptom control. While traditional pharmacotherapy remains essential in early-stage management, CNS implants such as deep brain stimulation (DBS) have become the gold standard for advanced Parkinson’s disease, offering significant improvements in motor function and quality of life^14,15.

Despite undeniable clinical success, several challenges—including surgical risks, device limitations, and accessibility barriers—still restrict the broader application of these technologies. However, ongoing research and innovation, including the development of adaptive DBS systems, AI-driven stimulation algorithms, and minimally invasive devices, promise to address many of these limitations in the near future¹⁶.

Recent patents and emerging inventions reflect the fast-paced evolution of the field, aiming toward more personalized, efficient, and safer neuromodulation therapies. With continued interdisciplinary research combining neuroscience, bioengineering, and clinical medicine, bioelectroceuticals hold great promise not only in managing symptoms but potentially in altering disease progression in Parkinson’s disease.

As advancements continue, CNS implants and other bioelectroceutical strategies are poised to redefine the standard of care for Parkinson’s disease, offering renewed hope for patients worldwide.

CONFLICT OF INTEREST:

The authors declare no conflict of interest regarding this review article.

ACKNOWLEDGMENTS:

The authors declare that no acknowledgments are applicable for this work.

REFERENCES:

1. Sivasubramanian N. Evidence based nursing education and practice. Asian J Nurs Educ Res. 2011 Jan-Mar;1(1):19-22.

2. Roja Princy. Multi methodology – research methodology for psychiatric nursing. Asian J Nurs Educ Res. 2011 Oct-Dec;1(4):120-2.

3. Patil PA, Patil DR, Jain AS, Shaikh AZ, Shaikh SR, Pawar SP. A review on Parkinson disease. Res J Sci Technol. 2025;17(3):231-8.

4. Bhong P, Ingale S, Jadhav P. Molecular mechanisms involved in pathogenesis of Parkinson's disease. Res J Pharm Technol. 2024;17(10):5167-74.

5. Acharya S, Meenambiga SS. Nanotechnology in Parkinson's disease – a review. Res J Pharm Technol. 2020;13(4):1965-9.

6. Patel YA, Narkhede K, Prajapati A, Narkhede S, Luhar S. AI-Driven Pharmacogenomics: The Future of Personalized Medicine . Asian J Pharm Technol. 2025;15(1):51-6.

7. Rani M, Sharma V. Medical implants: an overview, innovation and future prospects. Asian J Pharm Technol. 2025;15(2):157-65.

8. Kim WY. Design and implementation of electroceutical for neurotherapy. Int J Technol. 2021;11(2):63-9.

9. Prasad J, Netam AK, Singh R, Sahu M, Satapathy T, Rao SP, Baghel P, Sahu MK. Therapeutic approaches for the management of Parkinson’s disease. Res J Pharmacology Pharmacodyn. 2019;11(1):46-52.

10. Anoop Narayanan V, Narayana Charyulu R. Pharmacoelectronics and electropharmaceutics: the arts and science of electronic drug delivery. Res J Pharm Technol. 2017;10(10):3544-8.

11. M. M. Kachhi, S. R. Shinde and C. D. Bobade * School of Health Science and Technology, Department of Pharmaceutical Sciences, Dr. Vishwananth Karad MIT World Peace University, Kothrud, Pune - 411038, Maharashtra, India.

12. Lee SK, Jeakins GS, Tukiainen A, Hewage E and Armitage OE: Next-Generation Bioelectric Medicine: Harnessing the Therapeutic Potential of Neural Implants. Bioelectricity 2020; 2(4): 321-327. doi: 10.1089/bioe.2020.0044. Epub 2020 Dec 16. PMID: 34476364; PMCID: PMC8370382.

13. Lo MC, Widge AS. Closed-loop neuromodulation systems: Next-generation treatments for psychiatric illness. Int Rev Psychiatry. 2017;29(2)

14. Birmingham K, Gradinaru V, Anikeeva P, Grill WM, Pikov V, McLaughlin B, et al. Bioelectronic medicines: A research roadmap. Nat Rev Drug Discov. 2014;13(6):399–400.

15. Famm K, Litt B, Tracey KJ, Boyden ES, Slaoui M. A jump-start for electroceuticals. Nature. 2013;496(7444):159–161.

16. Benabid AL, Pollak P, Louveau A, Henry S, de Rougemont J. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol. 1987;50(1-6):344–346.

Received on 04.09.2025 Revised on 08.10.2025

Accepted on 19.11.2025 Published on 10.12.2025

Available online from December 26, 2025

International Journal of Technology. 2025; 15(2):56-61.

DOI: 10.52711/2231-3915.2025.00011

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.